International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Lixisenatide (Primary) ; Insulin; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms LixiRam
- Sponsors Sanofi
- 21 Jun 2017 Planned End Date changed from 30 Sep 2017 to 24 Jul 2017.
- 21 Jun 2017 Planned primary completion date changed from 30 Sep 2017 to 24 Jul 2017.
- 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.